FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382806935> ?p ?o ?g. }

• W4382806935 endingPage "S146" @default.
• W4382806935 startingPage "S146" @default.
• W4382806935 abstract "In metastatic colorectal cancer (mCRC) the choice of treatment should take into account the characteristics of the tumor and the patient, as well as its efficacy and tolerability. The RECOURSE study demonstrated that the presence of low tumor burden and indolent disease has an impact on progression-free (PFS) and overall (OS) survival of patients treated with trifluridine/tipiracil (TAS-102). Retrospective study that included mCRC patients undergoing TAS-102 from January 2017 to December 2021. The analysis was performed considering two subgroups: good prognosis (GP) - (1 or 2 metastasis sites and time ≥ 18 months since metastasis diagnosis to initiation of TAS-102) and poor prognosis (PP) - (≥ 3 metastasized sites and/or time < 18 months since metastasis diagnosis to TAS-102 initiation). Survival analysis was performed using the Kaplan-Meier method and the log-rank test. The prognostic impact was assessed using the Cox regression model. A total of 85 patients were included, 51.8% (n=44) male, with a median age of 65 years [24-85]. About 58.8% (n=50) were metastasized at diagnosis and 61.2% had a mutation in the RAS gene. About 80% (n=68) had an ECOG performance status of 0-1, 45.9% (n=39) had ≥ 3 metastatic sites and 72.9% (n=62) had liver metastases. In the total sample, 48.2% (n=41) had characteristics of GP and 51.8% (n=44) of PP. In 84.7% (n=72) of patients, TAS-102 was performed in the 3rd or 4th line of treatment. Median follow-up was 3 months (1-18). There was a statistically significant impact on OS and PFS of patients treated with TAS-102 taking into account the two prognostic subgroups (median PFS GP 5 months, 95%CI 4.1-5.9 versus PP 3 months, 95%CI 2.5-3.6, p=0.001; median OS GP 13 months, 95%CI 7.4-18.6 versus PP 5 months, 95%CI 4.3-5.7, p < 0.001). In the multivariate analysis, the presence of GP features was identified as an independent prognostic factor with an impact on PFS (HR 0.52, 95%CI 0.3-0.9, p=0.017) and OS (HR 0.47, 95%CI 0.3-0.8, p=0.004). Mutated RAS tumors were associated to a worse prognosis (HR 1.7, 95%CI 1.7-2.8, p=0.035). In our analysis, greater efficacy of TAS-102 was observed in the presence of GHP features in mCRC. Taking into account the advanced stage of the disease, the patient's vulnerability and socio-economic impact, the selection of patients who benefit from this therapy becomes increasingly relevant in an attempt to avoid therapeutic obstinacy and the underlying iatrogenesis." @default.
• W4382806935 created "2023-07-02" @default.
• W4382806935 creator A5002046574 @default.
• W4382806935 creator A5013742163 @default.
• W4382806935 creator A5017579982 @default.
• W4382806935 creator A5042931998 @default.
• W4382806935 creator A5050297025 @default.
• W4382806935 creator A5051559315 @default.
• W4382806935 creator A5051726777 @default.
• W4382806935 creator A5061272869 @default.
• W4382806935 creator A5071265779 @default.
• W4382806935 creator A5077647321 @default.
• W4382806935 creator A5083706045 @default.
• W4382806935 creator A5090896431 @default.
• W4382806935 date "2023-06-01" @default.
• W4382806935 modified "2023-09-26" @default.
• W4382806935 title "P-377 Prognostic stratification of TAS-102 treatment" @default.
• W4382806935 doi "https://doi.org/10.1016/j.annonc.2023.04.433" @default.
• W4382806935 hasPublicationYear "2023" @default.
• W4382806935 type Work @default.
• W4382806935 citedByCount "0" @default.
• W4382806935 crossrefType "journal-article" @default.
• W4382806935 hasAuthorship W4382806935A5002046574 @default.
• W4382806935 hasAuthorship W4382806935A5013742163 @default.
• W4382806935 hasAuthorship W4382806935A5017579982 @default.
• W4382806935 hasAuthorship W4382806935A5042931998 @default.
• W4382806935 hasAuthorship W4382806935A5050297025 @default.
• W4382806935 hasAuthorship W4382806935A5051559315 @default.
• W4382806935 hasAuthorship W4382806935A5051726777 @default.
• W4382806935 hasAuthorship W4382806935A5061272869 @default.
• W4382806935 hasAuthorship W4382806935A5071265779 @default.
• W4382806935 hasAuthorship W4382806935A5077647321 @default.
• W4382806935 hasAuthorship W4382806935A5083706045 @default.
• W4382806935 hasAuthorship W4382806935A5090896431 @default.
• W4382806935 hasBestOaLocation W43828069351 @default.
• W4382806935 hasConcept C121608353 @default.
• W4382806935 hasConcept C126322002 @default.
• W4382806935 hasConcept C143998085 @default.
• W4382806935 hasConcept C167135981 @default.
• W4382806935 hasConcept C197934379 @default.
• W4382806935 hasConcept C2776694085 @default.
• W4382806935 hasConcept C2776907518 @default.
• W4382806935 hasConcept C2778375690 @default.
• W4382806935 hasConcept C2779013556 @default.
• W4382806935 hasConcept C50382708 @default.
• W4382806935 hasConcept C526805850 @default.
• W4382806935 hasConcept C66339696 @default.
• W4382806935 hasConcept C71924100 @default.
• W4382806935 hasConcept C90924648 @default.
• W4382806935 hasConceptScore W4382806935C121608353 @default.
• W4382806935 hasConceptScore W4382806935C126322002 @default.
• W4382806935 hasConceptScore W4382806935C143998085 @default.
• W4382806935 hasConceptScore W4382806935C167135981 @default.
• W4382806935 hasConceptScore W4382806935C197934379 @default.
• W4382806935 hasConceptScore W4382806935C2776694085 @default.
• W4382806935 hasConceptScore W4382806935C2776907518 @default.
• W4382806935 hasConceptScore W4382806935C2778375690 @default.
• W4382806935 hasConceptScore W4382806935C2779013556 @default.
• W4382806935 hasConceptScore W4382806935C50382708 @default.
• W4382806935 hasConceptScore W4382806935C526805850 @default.
• W4382806935 hasConceptScore W4382806935C66339696 @default.
• W4382806935 hasConceptScore W4382806935C71924100 @default.
• W4382806935 hasConceptScore W4382806935C90924648 @default.
• W4382806935 hasLocation W43828069351 @default.
• W4382806935 hasOpenAccess W4382806935 @default.
• W4382806935 hasPrimaryLocation W43828069351 @default.
• W4382806935 hasRelatedWork W1908989187 @default.
• W4382806935 hasRelatedWork W1970423756 @default.
• W4382806935 hasRelatedWork W2071894746 @default.
• W4382806935 hasRelatedWork W2384405561 @default.
• W4382806935 hasRelatedWork W2419399195 @default.
• W4382806935 hasRelatedWork W2465617904 @default.
• W4382806935 hasRelatedWork W2542604898 @default.
• W4382806935 hasRelatedWork W3022070425 @default.
• W4382806935 hasRelatedWork W3172486966 @default.
• W4382806935 hasRelatedWork W3179015302 @default.
• W4382806935 hasVolume "34" @default.
• W4382806935 isParatext "false" @default.
• W4382806935 isRetracted "false" @default.
• W4382806935 workType "article" @default.